Three key questions dominate the agency’s Breakthrough Therapy Designation program since its 2012 launch.
Christopher-Paul Milne
Advertisement
Articles by Christopher-Paul Milne
Meeting Unmet Medical Needs: The Disparity Dilemma
Published: | Updated:
The US drug regulatory system fails to address the country’s most urgent medical needs with the resources appropriate for the task. But change is possible.
Advertisement
Latest Updated Articles
Meeting Unmet Medical Needs: The Disparity DilemmaPublished: February 1st 2015 | Updated: November 15th 2020
FDA’s Breakthrough Therapy DesignationPublished: September 8th 2015 | Updated: November 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
3
FDA Approves Hernexeos Under National Priority Voucher Program
4
Leading in the Psychedelic Space: Q&A with Tarek Rabah
5